Retrospective trial utilizing intraoperative radiation therapy with the revolutionary Xoft System
shows recurrence rates to be comparable to cornerstone TARGIT-A Trial at mean follow-up 4.6 years
NASHUA, N.H., Oct. 01, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions, today announced the results of a long-term, independent study conducted with the Xoft®
Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer
using intraoperative radiation therapy (IORT). With a mean follow-up of 55 months, outcomes published in The American Journal
of Surgery showed that breast cancer recurrence rates of patients who were treated with IORT using the Xoft System and
complied with adjuvant medical therapy were comparable to those seen in the cornerstone TARGIT-A study, which evaluated IORT using
different technology. To date, this study presents the most long-term research of IORT using the Xoft System published in a
peer-reviewed journal.
The retrospective study, Application of 21-gene recurrence score results and ASTRO suitability criteria in breast cancer
patients treated with intraoperative radiation therapy (IORT), evaluated the American Society for Radiation Oncology (ASTRO)
suitability criteria for APBI and the 21-gene recurrence score for prognostic and predictive benefit in IORT patients over a nearly
five-year period. The research was led by Barbara Schwartzberg, MD, FACS, conducted at the Rose Medical Center in Denver, Colo.,
and was not company sponsored.
“As the growing body of clinical evidence supporting the use of the Xoft System for IORT continues to mature and expand, we are
thrilled to see members of our global base of clinical users publishing landmark results that validate the long-term effectiveness
of our unique technology,” said Ken Ferry, CEO of iCAD. “The compelling findings, comparable to other IORT methods previously
examined, show IORT with the Xoft System is successful in delivering positive outcomes for patients with early-stage breast cancer
that comply with their full course of treatment.”
The study reviewed results of 184 patients with breast cancer from November 2011 to January 2016 completing Institutional Review
Board (IRB)-approved IORT protocol. Data included demographics, histopathology, the 21-gene recurrence score, adjuvant therapy,
locoregional and distant recurrences, and breast cancer-specific survival. All patients were classified by ASTRO suitability
criteria (suitable: 64 percent, cautionary: 30 percent, unsuitable: 6 percent), with a mean follow-up of 55 months.
Among the key findings:
- The recurrence rate for the 184 total IORT patients was 5.4 percent at a mean follow-up of 55 months; however, the recurrence
rate was significantly lower – 2 percent – for the patients who complied with adjuvant medical therapy. The difference in
recurrence rates between the group complying with versus declining adjuvant medical therapy was statistically significant.
- Adjuvant medical therapy was recommended to patients by their medical oncologists as a standard of care. Treatment included
either chemotherapy and/or endocrine therapy as dictated by molecular subtype and, if appropriate, the 21-gene recurrence score.
- These results are similar to the TARGIT-A study, which compared risk-adapted radiotherapy using single-dose targeted
intraoperative radiotherapy (TARGIT) to fractionated external beam radiotherapy (EBRT) for breast cancer. When TARGIT was
administered at the time of lumpectomy, the trial showed the 5-year local recurrence rates were 2.1% for TARGIT vs. 1.1% for
EBRT. The study concluded that IORT is non-inferior to EBRT.
"IORT continues to hold tremendous promise in the treatment of early-stage breast cancer. As our study shows, using IORT with
the Xoft System, combined with other post-operative therapy, proved extremely effective in addressing early-stage breast cancer and
preventing recurrences," said Barbara S. Schwartzberg, MD, FACS, lead author of the study and breast surgeon at Rose Medical
Center. “Furthermore, we saw the Oncotype DX 21-gene recurrence score is useful in its predictive benefit when applied to IORT
patients with invasive cancer. We believe that our results make a strong case for ASTRO suitability criteria for APBI to be amended
to reflect patients' eligibility for IORT treatment, since they were not initially designed to provide guidelines for patients
considering IORT.”
IORT with the Xoft System uses a miniaturized X-ray source to deliver one precise, concentrated dose of radiation to a tumor
site at the time of breast-conserving surgery (lumpectomy). The treatment can be completed in as little as eight minutes, making it
possible for appropriately selected patients to replace six to eight weeks of post-operative EBRT with a single treatment. The
Xoft System is cleared by the U.S. Food and Drug Administration, CE marked, and licensed in a growing number of countries for the
treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers.
It has been used to successfully treat more than 15,000 patients worldwide.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy
solutions. For more information, visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and
strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or
difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance,
possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in
Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the
effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”,
“project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking
statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date
the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with
the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2017, available on the Investors section
of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
paul@arpr.com
Investor Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568
jeremy@lifesciadvisors.com
